In this episode, legendary Canadian drug policy reform advocate **Alison Myrden** shares why patient advocacy and scientific research are vital for chronic pain care using medical cannabis and psilocybin.
Living with multiple sclerosis and severe chronic pain from Trigeminal Neuralgia (often dubbed the "suicide disease"), Alison became one of the first people in Canada to receive a federal exemption to legally use medical cannabis.
**In this episode, we explore:**
• **The State of Research:** Why psilocybin trials for pain management must catch up to cannabis.
• **Legal & Regulatory Barriers:** The institutional hurdles researchers face under current drug policies.
• **Alison's Journey:** Decades of pioneering compassionate healthcare, harm reduction, and reform.
**Episode Timestamps:**
**00:00** Why Legal Research Matters
**00:33** Podcast Intro
**01:22** Meet Alison Myrden
**02:32** Early Cannabis and MS Symptoms
**05:10** Diagnosis Delays and Mislabels
**08:09** Gary’s Support and Surgeries
**10:48** Meds vs Cannabis Relief
**11:33** Supplements and Vitamin D Regimen
**15:27** Website and Advocacy Origins
**16:25** Work, Mobility, and Staying Positive
**19:49** Trigeminal Pain and Psilocybin Discovery
**22:43** From Opioids to Drug Law Reform
**29:50** Psilocybin Dosing and Rapid Relief
**31:24** Suicide Level Pain
**32:05** Trauma After Episodes
**32:58** Beating MS Mobility Odds
**34:29** Advocacy Origins and LEAP
**38:27** Exoneration from Cannabis Records
**41:00** Protest and Key Organizations
**43:37** Podcasts and Sharing the Message
**45:52** Treatment Advice and Dosing
**49:02** Legal Fight for Access
**52:50** From Opioids to Natural Relief
**54:50** Supplements and Liver Protection
**59:41** Closing Thoughts on Support
**Connect with Alison Myrden:** https://alisonmyrden.ca
**Theme Music:** “Hold You” – Q-Black (licensed)
**Disclaimer:** This content is for educational and historical documentation purposes only. It depicts federally authorized medical cannabis administration in Canada for chronic pain management. This channel does not encourage or promote the illegal use of regulated substances.